Loading Pathway... 
Error: Pathway image not found.
Hide 
    Pathway Description
      Moxifloxacin Action Pathway
Haemophilus influenzae
          Drug Action Pathway
          
        
          Moxifloxacin is a fluoroquinolone antibiotic used to treat various bacterial infections. Moxifloxacin inhibits DNA gyrase (topoisomerase II) and topoisomerase IV. These proteins prevent supercoiling in bacterial DNA. The inhibition of DNA gyrase (topoisomerase II) and topoisomerase IV causes supercoiling of the bacterial DNA. This prevents DNA replication.
        
      References
      
      Moxifloxacin Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
                  Pubmed: 29126136
              Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. doi: 10.1038/nrd2132.
                  Pubmed: 17016423
              Schafer J, Hovde LB, Simonson D, Rotschafer JC: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. doi: 10.1016/j.diagmicrobio.2007.08.005. Epub 2007 Oct 29.
                  Pubmed: 17910998
              Deryke CA, Du X, Nicolau DP: Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep;58(3):601-9. doi: 10.1093/jac/dkl292. Epub 2006 Jul 19.
                  Pubmed: 16857688
              Perez-Vazquez M, Roman F, Aracil B, Canton R, Campos J: Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations. J Clin Microbiol. 2004 Mar;42(3):1185-91. doi: 10.1128/JCM.42.3.1185-1191.2004.
                  Pubmed: 15004073
              Highlighted elements will appear in red.
        
          
          
        
      
      Highlight Compounds
      Highlight Proteins
      Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
        
          
          
        
      
      Visualize Compound Data
      Visualize Protein Data
      Downloads
      
    Settings